Overview
Detection of tumor burden via circulating tumor DNA (ctDNA) can identify therapeutic response or resistance months in advance, and monitoring clinically actionable variant dynamics may be important for guiding treatment. Despite this, adoption has been slow due to the reduced sensitivity and reproducibility of current approaches. Here, we profile melanoma patients receiving ICI over several years using an ultra-sensitive tumor-informed ctDNA platform, and correlate the findings with clinical outcome.
